JP2019502095A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019502095A5 JP2019502095A5 JP2018519871A JP2018519871A JP2019502095A5 JP 2019502095 A5 JP2019502095 A5 JP 2019502095A5 JP 2018519871 A JP2018519871 A JP 2018519871A JP 2018519871 A JP2018519871 A JP 2018519871A JP 2019502095 A5 JP2019502095 A5 JP 2019502095A5
- Authority
- JP
- Japan
- Prior art keywords
- hmwk
- subject
- level
- disease
- sample
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102100035792 Kininogen-1 Human genes 0.000 claims 51
- 108010000487 High-Molecular-Weight Kininogen Proteins 0.000 claims 49
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 28
- 201000010099 disease Diseases 0.000 claims 23
- 238000000034 method Methods 0.000 claims 16
- 238000003018 immunoassay Methods 0.000 claims 14
- 239000000523 sample Substances 0.000 claims 14
- 239000012472 biological sample Substances 0.000 claims 10
- 239000003795 chemical substances by application Substances 0.000 claims 10
- 239000003814 drug Substances 0.000 claims 8
- 229940124597 therapeutic agent Drugs 0.000 claims 8
- 239000013068 control sample Substances 0.000 claims 7
- 239000003112 inhibitor Substances 0.000 claims 6
- 230000001404 mediated effect Effects 0.000 claims 5
- 206010010904 Convulsion Diseases 0.000 claims 4
- 108010058188 Low-Molecular-Weight Kininogen Proteins 0.000 claims 4
- 102000003827 Plasma Kallikrein Human genes 0.000 claims 4
- 108090000113 Plasma Kallikrein Proteins 0.000 claims 4
- 238000003556 assay Methods 0.000 claims 3
- 210000004369 blood Anatomy 0.000 claims 3
- 239000008280 blood Substances 0.000 claims 3
- 239000003446 ligand Substances 0.000 claims 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims 2
- 101800004538 Bradykinin Proteins 0.000 claims 2
- 102000055157 Complement C1 Inhibitor Human genes 0.000 claims 2
- 108700040183 Complement C1 Inhibitor Proteins 0.000 claims 2
- 238000002965 ELISA Methods 0.000 claims 2
- QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 claims 2
- QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 claims 2
- 229940009550 c1 esterase inhibitor Drugs 0.000 claims 2
- 238000003776 cleavage reaction Methods 0.000 claims 2
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 claims 2
- QURWXBZNHXJZBE-SKXRKSCCSA-N icatibant Chemical compound NC(N)=NCCC[C@@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2SC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@H](CC3=CC=CC=C3C2)C(=O)N2[C@@H](C[C@@H]3CCCC[C@@H]32)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O)C[C@@H](O)C1 QURWXBZNHXJZBE-SKXRKSCCSA-N 0.000 claims 2
- 108700023918 icatibant Proteins 0.000 claims 2
- 229960001062 icatibant Drugs 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 230000007017 scission Effects 0.000 claims 2
- 210000002966 serum Anatomy 0.000 claims 2
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 1
- 238000012286 ELISA Assay Methods 0.000 claims 1
- 108010090804 Streptavidin Proteins 0.000 claims 1
- 229960002685 biotin Drugs 0.000 claims 1
- 235000020958 biotin Nutrition 0.000 claims 1
- 239000011616 biotin Substances 0.000 claims 1
- 230000000903 blocking effect Effects 0.000 claims 1
- 238000003119 immunoblot Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 238000001262 western blot Methods 0.000 claims 1
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021104359A JP7238027B2 (ja) | 2015-10-19 | 2021-06-23 | 切断高分子量キニノーゲンを検出するイムノアッセイ |
| JP2023031415A JP7640599B2 (ja) | 2015-10-19 | 2023-03-01 | 切断高分子量キニノーゲンを検出するイムノアッセイ |
| JP2025025949A JP2025081553A (ja) | 2015-10-19 | 2025-02-20 | 切断高分子量キニノーゲンを検出するイムノアッセイ |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562243505P | 2015-10-19 | 2015-10-19 | |
| US62/243,505 | 2015-10-19 | ||
| US201662335311P | 2016-05-12 | 2016-05-12 | |
| US62/335,311 | 2016-05-12 | ||
| PCT/US2016/057640 WO2017070170A1 (en) | 2015-10-19 | 2016-10-19 | Immunoassay to detect cleaved high molecular weight kininogen |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021104359A Division JP7238027B2 (ja) | 2015-10-19 | 2021-06-23 | 切断高分子量キニノーゲンを検出するイムノアッセイ |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019502095A JP2019502095A (ja) | 2019-01-24 |
| JP2019502095A5 true JP2019502095A5 (enExample) | 2019-11-28 |
| JP6903648B2 JP6903648B2 (ja) | 2021-07-14 |
Family
ID=57233867
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018519871A Active JP6903648B2 (ja) | 2015-10-19 | 2016-10-19 | 切断高分子量キニノーゲンを検出するイムノアッセイ |
| JP2021104359A Active JP7238027B2 (ja) | 2015-10-19 | 2021-06-23 | 切断高分子量キニノーゲンを検出するイムノアッセイ |
| JP2023031415A Active JP7640599B2 (ja) | 2015-10-19 | 2023-03-01 | 切断高分子量キニノーゲンを検出するイムノアッセイ |
| JP2025025949A Pending JP2025081553A (ja) | 2015-10-19 | 2025-02-20 | 切断高分子量キニノーゲンを検出するイムノアッセイ |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021104359A Active JP7238027B2 (ja) | 2015-10-19 | 2021-06-23 | 切断高分子量キニノーゲンを検出するイムノアッセイ |
| JP2023031415A Active JP7640599B2 (ja) | 2015-10-19 | 2023-03-01 | 切断高分子量キニノーゲンを検出するイムノアッセイ |
| JP2025025949A Pending JP2025081553A (ja) | 2015-10-19 | 2025-02-20 | 切断高分子量キニノーゲンを検出するイムノアッセイ |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US10914747B2 (enExample) |
| EP (3) | EP3365685B1 (enExample) |
| JP (4) | JP6903648B2 (enExample) |
| KR (2) | KR102698737B1 (enExample) |
| CN (2) | CN113655228B (enExample) |
| AU (2) | AU2016340826C1 (enExample) |
| BR (1) | BR112018007842A2 (enExample) |
| CA (1) | CA3002747A1 (enExample) |
| CO (1) | CO2018004289A2 (enExample) |
| DK (1) | DK3365685T3 (enExample) |
| EA (1) | EA201891002A1 (enExample) |
| ES (2) | ES2857552T3 (enExample) |
| IL (2) | IL258637B2 (enExample) |
| MX (2) | MX2018004763A (enExample) |
| PL (2) | PL3839514T3 (enExample) |
| PT (1) | PT3365685T (enExample) |
| WO (1) | WO2017070170A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111044725B (zh) | 2013-01-20 | 2024-03-29 | 武田药品工业株式会社 | 缓激肽介导的病症的评估和治疗 |
| PT3060908T (pt) | 2013-10-21 | 2021-05-27 | Dyax Corp | Diagnóstico e tratamento de doenças autoimunes |
| KR20250066486A (ko) | 2013-10-21 | 2025-05-13 | 다케다 파머수티컬 컴패니 리미티드 | 혈장 칼리크레인 시스템 바이오마커를 결정하기 위한 검정법 |
| JP6903648B2 (ja) | 2015-10-19 | 2021-07-14 | ダイアックス コーポレーション | 切断高分子量キニノーゲンを検出するイムノアッセイ |
| US11525002B2 (en) | 2017-10-11 | 2022-12-13 | Board Of Regents, The University Of Texas System | Human PD-L1 antibodies and methods of use therefor |
| EP4501355A3 (en) | 2018-03-23 | 2025-04-30 | Board Of Regents, The University Of Texas System | Dual specificity antibodies to pd-l1 and pd-l2 and methods of use therefor |
| CN119101158A (zh) | 2018-03-23 | 2024-12-10 | 得克萨斯州大学系统董事会 | 人pd-l2抗体及其使用方法 |
| CN117586412A (zh) | 2018-03-23 | 2024-02-23 | 得克萨斯州大学系统董事会 | 针对人pd-l1和pd-l2的双重特异性抗体及其使用方法 |
| WO2020004490A1 (ja) * | 2018-06-26 | 2020-01-02 | 協和キリン株式会社 | コンドロイチン硫酸プロテオグリカン－５に結合する抗体 |
Family Cites Families (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1312564C (en) | 1985-07-12 | 1993-01-12 | Robert W. Colman | Monoclonal antibodies to human plasma prekallikrein and methods of preparing and using same |
| US5047323A (en) * | 1986-01-22 | 1991-09-10 | Temple University Of The Commonwealth System Of Higher Education | Method for detecting human kininogen using monoclonal antibodies thereto |
| US4908431A (en) | 1986-01-22 | 1990-03-13 | Temple University-Of The Commonwealth System Of Higher Education | Monoclonal antibodies to human kininogen and methods of preparing same |
| US4704692A (en) | 1986-09-02 | 1987-11-03 | Ladner Robert C | Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| KR960009766B1 (ko) | 1986-09-10 | 1996-07-24 | 니혼 소오끼 세이야꾸 가부시기가이샤 | 생리 활성물질 측정법 |
| US4882272A (en) | 1986-10-01 | 1989-11-21 | Temple University - Of The Commonwealth System Of Higher Education | High molecular weight kininogen assay |
| US5025796A (en) | 1988-12-01 | 1991-06-25 | The United States Of America As Represented By The Department Of Health And Human Services | Apparatus and methods for determining in vivo response to thermal stimulation in in an unrestrained subject |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| WO1993003748A1 (en) | 1991-08-13 | 1993-03-04 | Temple University - Of The Commonwealth System Of Higher Education | Modulation of blood pressure and inhibition of platelet activation with kininogen fragment |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| EP0739355B1 (en) | 1994-01-11 | 2004-09-08 | Dyax Corporation | Kallikrein-inhibiting "kunitz domain" proteins and analogues thereof |
| US6057287A (en) | 1994-01-11 | 2000-05-02 | Dyax Corp. | Kallikrein-binding "Kunitz domain" proteins and analogues thereof |
| US6265150B1 (en) | 1995-06-07 | 2001-07-24 | Becton Dickinson & Company | Phage antibodies |
| JPH1084995A (ja) * | 1996-09-12 | 1998-04-07 | Nippon Zoki Pharmaceut Co Ltd | 血液凝固第ｘｉｉ因子活性化法 |
| US5789261A (en) * | 1996-10-30 | 1998-08-04 | Temple University Of The Commonwealth System Of Higher Education | Solid phase immunoassay |
| US6242210B1 (en) | 1997-05-20 | 2001-06-05 | Actinova Limited | Treatment of bacterial infections |
| JP4346798B2 (ja) * | 1999-08-19 | 2009-10-21 | 協和メデックス株式会社 | Ｈｃｖコア抗原の検出または定量方法およびそれに用いる検出または定量試薬。 |
| US6994852B1 (en) | 1999-11-12 | 2006-02-07 | Temple University-Of The Commonwealth System Of Higher Education | Inhibition of angiogenesis by antibodies against high molecular weight kininogen domain 5 |
| US7067713B2 (en) | 2000-01-31 | 2006-06-27 | Pharming Intellectual Property B.V. | C1 Inhibitor produced in the milk of transgenic non-human mammals |
| US7678541B2 (en) | 2000-11-21 | 2010-03-16 | Hologic, Inc. | Methods and compositions for the detection of a nucleic acid using a non-invasive cleavage reaction |
| JP2002221519A (ja) * | 2001-01-29 | 2002-08-09 | Sysmex Corp | 抗凝固剤およびそれを用いた抗凝固剤処理方法 |
| US20040152633A1 (en) | 2001-05-31 | 2004-08-05 | Jorgensen Marianne Ulrich | Kunitz-type sequences and polypeptides |
| US6913900B2 (en) * | 2001-08-29 | 2005-07-05 | Nippon Zoki Pharmaceutical Co., Ltd. | Plasma prekallikrein activation and kallikrein production assay |
| ATE528014T1 (de) | 2002-06-07 | 2011-10-15 | Dyax Corp | Polypeptid mit modifizierten kunitz domains |
| WO2004005934A2 (en) | 2002-07-04 | 2004-01-15 | Oxford Glycosciences (Uk) Ltd | Toxicity markers |
| US20070003552A1 (en) | 2002-07-09 | 2007-01-04 | Gebbink Martijn F B | Cross-beta structure comprising amyloid binding proteins and methods for detection of the cross-beta structure, for modulating cross-beta structures fibril formation and for modulating cross-beta structure-mediated toxicity and method for interfering with blood coagulation |
| EP1598428A1 (en) | 2004-05-18 | 2005-11-23 | Georg Dewald | Methods and kits to detect Hereditary angioedema type III |
| WO2006017538A2 (en) | 2004-08-03 | 2006-02-16 | Dyax Corp. | Hk1-binding proteins |
| US7235530B2 (en) | 2004-09-27 | 2007-06-26 | Dyax Corporation | Kallikrein inhibitors and anti-thrombolytic agents and uses thereof |
| LT1981519T (lt) | 2005-12-29 | 2018-04-25 | Dyax Corp. | Proteazės slopinimas |
| US7276480B1 (en) | 2005-12-30 | 2007-10-02 | Dyax Corp. | Prevention and reduction of blood loss |
| US7625944B2 (en) | 2006-07-31 | 2009-12-01 | Activesite Pharmaceuticals, Inc. | Inhibitors of plasma kallikrein |
| JP2010510528A (ja) | 2006-11-22 | 2010-04-02 | ライフ テクノロジーズ コーポレーション | 自己免疫疾患のバイオマーカー |
| WO2009026334A2 (en) | 2007-08-21 | 2009-02-26 | Genzyme Corporation | Treatment with kallikrein inhibitors |
| EP2216651A4 (en) | 2007-10-18 | 2010-12-01 | Miyazaki Prefectural Ind Suppo | BIOMARKERS FOR THE DIAGNOSIS OF LIVER DISEASE |
| WO2009053050A1 (en) | 2007-10-22 | 2009-04-30 | Georg Dewald | Disorders of vasoregulation and methods of diagnosing them |
| JP5348595B2 (ja) | 2008-07-07 | 2013-11-20 | 日本臓器製薬株式会社 | 線維筋痛症の検査法 |
| JP2012507723A (ja) | 2008-11-03 | 2012-03-29 | シェーリング コーポレイション | 炎症性腸疾患生物マーカーおよび関連治療方法 |
| EP2369930A4 (en) | 2008-12-02 | 2012-10-03 | Joslin Diabetes Ct | METHOD OF REDUCING BLOOD PRESSURE USING PLASMATIC KALLICREIN INHIBITORS |
| JP2013516389A (ja) | 2009-01-06 | 2013-05-13 | ダイアックス コーポレーション | カリクレイン阻害剤による粘膜炎治療 |
| FR2942233B1 (fr) * | 2009-02-19 | 2015-03-13 | Lfb Biotechnologies | Moyens pour la purification d'une proteine du plasma sanguin, et procedes pour sa mise en oeuvre |
| KR101077275B1 (ko) | 2009-05-07 | 2011-10-27 | 한국기초과학지원연구원 | 당단백질의 당쇄화를 이용한 암 진단 방법 |
| JP5299179B2 (ja) | 2009-09-02 | 2013-09-25 | 株式会社リコー | 画像形成装置 |
| JO3244B1 (ar) | 2009-10-26 | 2018-03-08 | Amgen Inc | بروتينات ربط مستضادات il – 23 البشرية |
| US9206123B2 (en) | 2009-12-18 | 2015-12-08 | Activesite Pharmaceuticals, Inc. | Prodrugs of inhibitors of plasma kallikrein |
| CN102762203A (zh) | 2009-12-18 | 2012-10-31 | 艾克提弗赛特制药股份有限公司 | 血浆激肽释放酶抑制剂的前药 |
| ES2905545T3 (es) | 2010-01-06 | 2022-04-11 | Takeda Pharmaceuticals Co | Proteínas de unión a calicreína plasmática |
| EP2593121A2 (en) | 2010-07-13 | 2013-05-22 | University Of Rochester | THE cAMP/PKA/HDAC5 PATHWAY AND USES THEREOF |
| AU2011336345B2 (en) * | 2010-12-02 | 2016-07-07 | Becton, Dickinson And Company | Blood collection devices containing blood stabilization agent |
| IL269565B2 (en) | 2011-01-06 | 2024-06-01 | Dyax Corp | Plasma kallikrein binding proteins |
| AU2012267546B2 (en) | 2011-06-10 | 2015-12-24 | Ionis Pharmaceuticals, Inc. | Methods for modulating kallikrein (KLKB1) expression |
| US9187749B2 (en) | 2011-06-10 | 2015-11-17 | Isis Pharmaceuticals, Inc. | Methods for modulating factor 12 expression |
| FR2983215B1 (fr) | 2011-11-28 | 2013-12-20 | Univ Grenoble 1 | Dosage de la capacite de controle de c1inh |
| CN111044725B (zh) * | 2013-01-20 | 2024-03-29 | 武田药品工业株式会社 | 缓激肽介导的病症的评估和治疗 |
| US20140220552A1 (en) * | 2013-02-01 | 2014-08-07 | Becton, Dickinson And Company | Blood collection devices containing contact pathway inhibition additives |
| KR20250066486A (ko) * | 2013-10-21 | 2025-05-13 | 다케다 파머수티컬 컴패니 리미티드 | 혈장 칼리크레인 시스템 바이오마커를 결정하기 위한 검정법 |
| PT3060908T (pt) | 2013-10-21 | 2021-05-27 | Dyax Corp | Diagnóstico e tratamento de doenças autoimunes |
| KR102424183B1 (ko) * | 2014-01-21 | 2022-07-26 | 다케다 파머수티컬 컴패니 리미티드 | 혈장 칼리크레인 결합 단백질 및 유전성 혈관부종을 치료하는 데 있어서의 이의 용도 |
| JP6903648B2 (ja) * | 2015-10-19 | 2021-07-14 | ダイアックス コーポレーション | 切断高分子量キニノーゲンを検出するイムノアッセイ |
| EP3390439B1 (en) | 2015-12-15 | 2025-03-12 | Takeda Pharmaceutical Company Limited | Peptide quantitation assay for differentiating full-length high molecular weight kininogen (hmwk) and cleaved hmwk |
| WO2021094587A1 (en) | 2019-11-13 | 2021-05-20 | eV-Technologies | Spin-wave based magnetic and/or electro-magnetic field sensing device for dc, rf and millimeter-wave applications |
| US20230072523A1 (en) | 2020-01-28 | 2023-03-09 | Orgenesis Inc. | Process and system for acellular therapy |
-
2016
- 2016-10-19 JP JP2018519871A patent/JP6903648B2/ja active Active
- 2016-10-19 EP EP16791171.8A patent/EP3365685B1/en active Active
- 2016-10-19 CA CA3002747A patent/CA3002747A1/en active Pending
- 2016-10-19 EP EP20209278.9A patent/EP3839514B1/en active Active
- 2016-10-19 KR KR1020187014261A patent/KR102698737B1/ko active Active
- 2016-10-19 ES ES16791171T patent/ES2857552T3/es active Active
- 2016-10-19 PL PL20209278.9T patent/PL3839514T3/pl unknown
- 2016-10-19 PT PT167911718T patent/PT3365685T/pt unknown
- 2016-10-19 US US15/769,237 patent/US10914747B2/en active Active
- 2016-10-19 DK DK16791171.8T patent/DK3365685T3/da active
- 2016-10-19 BR BR112018007842-5A patent/BR112018007842A2/pt active Search and Examination
- 2016-10-19 CN CN202110923341.6A patent/CN113655228B/zh active Active
- 2016-10-19 IL IL258637A patent/IL258637B2/en unknown
- 2016-10-19 CN CN201680069922.5A patent/CN108291917B/zh active Active
- 2016-10-19 KR KR1020247027973A patent/KR20240133761A/ko active Pending
- 2016-10-19 MX MX2018004763A patent/MX2018004763A/es unknown
- 2016-10-19 PL PL16791171T patent/PL3365685T3/pl unknown
- 2016-10-19 WO PCT/US2016/057640 patent/WO2017070170A1/en not_active Ceased
- 2016-10-19 EA EA201891002A patent/EA201891002A1/ru unknown
- 2016-10-19 EP EP23215946.7A patent/EP4354146A3/en active Pending
- 2016-10-19 IL IL312916A patent/IL312916A/en unknown
- 2016-10-19 ES ES20209278T patent/ES2973301T3/es active Active
- 2016-10-19 AU AU2016340826A patent/AU2016340826C1/en active Active
-
2018
- 2018-04-18 MX MX2023005689A patent/MX2023005689A/es unknown
- 2018-04-23 CO CONC2018/0004289A patent/CO2018004289A2/es unknown
-
2021
- 2021-01-05 US US17/141,690 patent/US12493047B2/en active Active
- 2021-06-23 JP JP2021104359A patent/JP7238027B2/ja active Active
-
2023
- 2023-01-30 AU AU2023200462A patent/AU2023200462B2/en active Active
- 2023-03-01 JP JP2023031415A patent/JP7640599B2/ja active Active
-
2025
- 2025-02-20 JP JP2025025949A patent/JP2025081553A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019502095A5 (enExample) | ||
| US9134326B2 (en) | Biomarkers for liver fibrosis | |
| US7803553B2 (en) | Methods of use of antibodies which recognize a protease cleavage site of an LAP fragment of TGF-β | |
| JPWO2003085399A1 (ja) | 白血病、前白血病または非白血病性悪性血液疾患の判定方法及び診断薬 | |
| IL312916A (en) | An immunoassay for the detection of high molecular weight cleaved kininogen | |
| Burgener et al. | A systems biology examination of the human female genital tract shows compartmentalization of immune factor expression | |
| RU2707303C1 (ru) | Способ диагностики или мониторинга почечной функции или диагностики почечной дисфункции | |
| JP2019532633A5 (enExample) | ||
| US10379108B2 (en) | Distinction of infectious virus based on molecular biomarker and neutralization of virus causing food poisoning | |
| Chang et al. | The diagnosis and classification of autoimmune coagulopathy: an updated review | |
| EP4232147A1 (en) | Methods for identifying and treating antibody-mediated acquired primary or recurrent idiopathic nephrotic syndrome | |
| US20180284131A1 (en) | Diagnostic assays for supar-β3 integrin driven kidney diseases | |
| US20180136216A1 (en) | Biomarkers for a Combination Therapy Comprising Lenvatinib and Everolimus | |
| Wiederin et al. | Plasma proteomic analysis of simian immunodeficiency virus infection of rhesus macaques | |
| EP3861347A1 (en) | Biomarkers for a combination therapy comprising lenvatinib and everolimus | |
| JP6760562B2 (ja) | 卵巣明細胞癌患者の予後を予測するための情報提供方法 | |
| US11174310B2 (en) | Disulfide-type HMGB1-specific antibody, method for measuring disulfide-type HMGB1 and kit for said measurement, and measurement method capable of quantitating all of HMGB1 molecules including reduced HMGB1, disulfide-type HMGB1 and thrombin-cleavable HMGB1 and kit for said measurement | |
| US10295550B2 (en) | Compositions and methods for use in diagnosis of alzheimer's disease | |
| WO2016005369A1 (en) | Par2 antibodies for diagnosis of graft intolerance of a liver transplant | |
| Perico et al. | SARS-CoV-2 spike protein 1 activates microvascular endothelial cells and complement system leading to thrombus formation | |
| EP3177312B1 (en) | Method and kit for detecting bacterial infection | |
| US20240003915A1 (en) | Marker for assisting in diagnosis of nephrotic syndrome and use thereof | |
| JP6407990B2 (ja) | アウグリン免疫学的検定 | |
| US20220144939A1 (en) | Antibody therapies and methods for treating coronavirus infection | |
| NZ781429B2 (en) | Immunoassay for the detection of cleaved high molecular weight kininogen |